Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2008;10(4):219-35.
doi: 10.1007/s12017-008-8036-z. Epub 2008 Jun 10.

Neurological benefits of omega-3 fatty acids

Affiliations
Review

Neurological benefits of omega-3 fatty acids

S C Dyall et al. Neuromolecular Med. 2008.

Abstract

The central nervous system is highly enriched in long-chain polyunsaturated fatty acid (PUFA) of the omega-6 and omega-3 series. The presence of these fatty acids as structural components of neuronal membranes influences cellular function both directly, through effects on membrane properties, and also by acting as a precursor pool for lipid-derived messengers. An adequate intake of omega-3 PUFA is essential for optimal visual function and neural development. Furthermore, there is increasing evidence that increased intake of the long-chain omega-3 PUFA, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), may confer benefits in a variety of psychiatric and neurological disorders, and in particular neurodegenerative conditions. However, the mechanisms underlying these beneficial effects are still poorly understood. Recent evidence also indicates that in addition to the positive effects seen in chronic neurodegenerative conditions, omega-3 PUFA may also have significant neuroprotective potential in acute neurological injury. Thus, these compounds offer an intriguing prospect as potentially new therapeutic approaches in both chronic and acute conditions. The purpose of this article is to review the current evidence of the neurological benefits of omega-3 PUFA, looking specifically at neurodegenerative conditions and acute neurological injury.

PubMed Disclaimer

References

    1. Biomed Pharmacother. 2002 Jul;56(5):215-22 - PubMed
    1. Am J Clin Nutr. 2006 Jun;83(6 Suppl):1494S-1498S - PubMed
    1. Prog Neuropsychopharmacol Biol Psychiatry. 1998 Aug;22(6):1007-21 - PubMed
    1. Arch Neurol. 2005 Sep;62(9):1345-56 - PubMed
    1. Am J Clin Nutr. 2000 Jan;71(1 Suppl):376S-85S - PubMed

MeSH terms